Relationship of Body Weight Parameters with the Incidence of Common Spontaneous Tumors in Tg.rasH2 Mice

Abstract

The mechanistic relationship between increased food consumption, increased body weights, and increased incidence of tumors has been well established in 2-year rodent models. Body weight parameters such as initial body weights, terminal body weights, food consumption, and the body weight gains in grams and percentages were analyzed to determine whether such relationship exists between these parameters with the incidence of common spontaneous tumors in Tg.rasH2 mice. None of these body weight parameters had any statistically significant relationship with the incidence of common spontaneous tumors in Tg.rasH2 males, namely lung tumors, splenic hemangiosarcomas, nonsplenic hemangiosarcomas, combined incidence of all hemangiosarcomas, and Harderian gland tumors. These parameters also did not have any statistically significant relationship with the incidence of lung and Harderian gland tumors in females. However, in females, increased initial body weights did have a statistically significant relationship with the nonsplenic hemangiosarcomas, and increased terminal body weights did have a statistically significant relationship with the incidence of splenic hemangiosarcomas, nonsplenic hemangiosarcomas, and the combined incidence of all hemangiosarcomas. In addition, increased body weight gains in grams and percentages had a statistically significant relationship with the combined incidence of all hemangiosarcomas in females, but not separately with splenic and nonsplenic hemangiosarcomas.

Keywords

Tg.rasH2 tumors body weight parameters transgenic animals.

Introduction

During the preclinical phase of the drug discovery process, the safety studies that evaluate the toxic and carcinogenic potential of the drugs are conducted in rodents. Traditionally, the 2-year studies have been conducted in rat models such as F344 and Sprague-Dawley and in mouse models such as CD-1 and B6C3F1. Over the past decade since the transgenic mouse model Tg.rasH2 became available, these studies are now also being performed for a shorter duration of 26 weeks, replacing about a quarter of all 2-year carcinogenicity studies performed in conventional mouse models (Jacobs and Hatfield 2013; Nambiar, Turnquist, and Morton 2012; Paranjpe, Elbekai, et al. 2013).

According to the American Cancer Society (2012), obesity is clearly associated with a variety of cancers in human beings, such as those involving breast, colon and rectum, uterus, esophagus, kidney, and pancreas. Overweight people are also at increased risk of developing cancers of the liver and gall bladder, non-Hodgkin lymphoma, multiple myeloma, and cancers involving the ovaries and cervix. The relationship between increased food consumption, increased body weights, hormonal perturbations, increased incidence of tumors, and increased mortality that eventually complicate the interpretation of 2-year rodent studies has been widely reported in the 2-year F344 rats, Sprague-Dawley rats, CD-1 mice, and B6C3F1 mice (Allaben et al. 1996; Biegel et al. 2001; Hart et al. 1995; Haseman et al. 1997; Haseman, Hailey, and Morris 1998; Keenan and Soper 1995; Keenan et al. 1995; Leakey, Seng, and Allaben 2003; Nohynek et al. 1993; Nunez et al. 2008; Rao 1996; Roe 1981, 1993; Seilkop 1995; Sistare et al. 2011; Turturro et al. 1996). More specifically in the F344 rat, increased body weights have been associated with increased numbers of pituitary tumors and mononuclear cell leukemias in males, and pituitary tumors and mammary gland fibroadenomas in females. In the B6C3F1 mouse, increased body weights have been associated with an increased incidence of liver tumors in both sexes (Haseman, Bourbina, and Eustis 1994; Haseman 1995a, 1995b; Haseman et al. 1997; Haseman, Hailey, and Morris 1998; Kari and Abdo 1995; Rao, Piegorsch, and Haseman 1987; Thurman et al. 1994; Witt, Sheldon, and Thurman 1991).

In our laboratory, we performed twenty-six, 26-week short-term carcinogenicity studies using the Tg.rasH2 mouse model. The data pertaining to spontaneous tumors in these mice have been published (Paranjpe, Elbekai, et al. 2013). However, relationship of body weight parameters with the incidence of tumors in the Tg.rasH2 mice, if any, has not been published so far. The purpose of this publication is to determine whether any relationship exists between body weight parameters such as initial body weights, terminal body weights, food consumption, and the body weight gains in grams and percentages with the incidence of spontaneous tumors in this mouse model. Specifically, we evaluated the common spontaneous tumors in this strain of mouse (Nambiar, Turnquist, and Morton 2012; Paranjpe, Elbekai, et al. 2013), namely lung tumors (adenomas and carcinomas), splenic hemangiosarcomas, nonsplenic hemangiosarcomas, the combined incidence of all splenic and nonsplenic hemangiosarcomas, and Harderian gland tumors (adenomas and carcinomas).

Materials and Methods

Animals

CByB6F1-Tg(HRAS)2Jic (+/− hemizygous c-Ha-ras) mice, obtained from Taconic Farms (Germantown, NY), were used in all studies. The knock-in Tg element (human prototype c-Ha-ras gene with its own promoter/enhancer) is injected into C57BL/6 × BALB/c F2 zygotes, which are crossed back to C57BL/6J forming C57BL/6JJic-Tg(HRAS)2Jic. The CByB6F1-Tg(HRAS)2Jic (+/− hemizygous c-Ha-ras) is the offspring from a cross of the C57BL/6JJic-Tg(HRAS)2Jic hemizygous male mice with the BALB/cByJJic female mice. Each mouse was genotyped by Taconic to verify the presence of the transgene before being placed on study. Animals were assigned to groups using a computer-generated randomization program. On the first day of treatment, animals were 6 to 10 weeks of age and weighed at least 20 g or 15 g (males and females, respectively). Individual body weights for each dose group of each sex were within ±20% of the mean at the start of the study. Even though the starting age has varied between 6 and 10 weeks between studies, every attempt was made to start any given study around starting age of 8 weeks. However, the starting age of the mice on the study depended on the breeding schedules of the supplier, Taconic. Nevertheless, in any given study, the starting age of males and females was similar.

Housing and Environmental Conditions

Housing and environmental conditions were similar in all studies. Animals were single housed in polycarbonate cages with hardwood bedding chips in environmentally controlled rooms. Animals were verified to be free of illness prior to being placed on a study. All animals had ad libitum access to water and powdered feed (Harlan TEKLAD Global Diet, Madison, WI). While the lot numbers and the milling dates of the feed varied between the studies, in general, all batches of feed contained about 18.5% of protein, 6% of fat, and 3.5% of fiber. Each batch of feed was analyzed by the manufacturer for concentrations of specified heavy metals, aflatoxins, chlorinated hydrocarbons, organophosphates, and specified nutrients. The results of these analyses are on file at BioReliance. There were no contaminants in any of the batches of feed at levels that would interfere with the study.

Regulatory Requirements

The numbers of animals, procedures, and experimental design for each study were reviewed and approved by the BioReliance Institutional Animal Care and Use Committee (IACUC). All procedures followed the specifications recommended in The Guide for the Care and Use of Laboratory Animals and were conducted in an Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)-accredited facility. All procedures involving but not limited to quarantine and acclimation, randomization, application of unique identification system, housing, provision of food and water, administration of test article, recording of clinical signs, necropsy, and tissue processing were followed in strict accordance with the Good Laboratory Practice Regulations, Standard Operating Procedures, and protocol for each study.

Retrospective Analysis

The database was constructed based on Tg.rasH2 mice assigned to 26 studies conducted at our facility, following the same study design. The first of these studies was completed in 2004 and the last study was completed in 2012. Vehicle was administered to 710 male and 710 female mice by oral gavage (21 studies), dosed feed (3 studies), or intravenous injection (2 studies) for 26 weeks. Predose body weights were collected on day 1, and mice were weighed weekly thereafter for the next consecutive 13 weeks. After 13 weeks, the body weights were collected biweekly until the termination of the study at 26 weeks. Food consumption was recorded weekly for individual animals from day 1 until the termination of the study at 26 weeks. Upon the death or moribund sacrifice of an animal and at the termination of the study, all animals in each study were humanely sacrificed by CO₂ overdose and subjected to complete necropsy. Protocol required tissues were saved in 10% neutral buffered formalin, processed routinely, stained with hematoxylin and eosin, and evaluated microscopically. Each study was peer reviewed.

Common spontaneous tumors noted in Tg.rasH2 male and female mice were grouped as follows: (1) lung tumors (adenomas and carcinomas), (2) splenic hemangiosarcomas, (3) nonsplenic hemangiosarcomas, (4) combined incidence of all hemangiosarcomas (splenic and nonsplenic), and (5) Harderian gland tumors (adenomas and carcinomas).

For each tumor category listed previously, the summary statistics for the group with tumors versus the group without tumors were calculated by gender. The initial body weights, the terminal body weights, food consumption, and the body weight gains in grams and percentages between the animals with or without tumor were compared by the nonparametric Wilcoxon rank sum test (Hollander and Wolfe 1973). A two-sided version of the test was used, and the p value indicating the significance of the test is presented in the summary tables. Analysis for each body weight parameter was performed at 2 time points, half way through the study at 13 weeks and at terminal sacrifice at 26 weeks. In addition, the average initial body weights and total tumor counts for each tumor category for each sex were used to calculate the Pearson correlation coefficient to rule out if the higher initial body weights due to higher starting age had any influence on the incidence of tumors in either sex (Rodgers and Nicewander 1988). All calculations were performed using SAS Version 9.2. Throughout this article, the average initial body weights, average terminal body weights, average body weight gains in grams, and average daily food consumption are expressed as M ± SD.

Results

The information pertaining to the mortality/survival, body weight parameters, and the incidence of common spontaneous tumors in percentages is provided in Table 1. The mortality in both male and female mice was identical at 3.94%. The average initial body weights, average terminal body weights, and the body weight gains in grams of male mice, expressed as M ± SD were 23.41 ± 0.86, 29.39 ± 2.20, and 5.98 ± 2.08, respectively. The average initial body weights, average terminal body weights, and the body weight gains in grams of female mice were 18.74 ± 0.60, 23.56 ± 0.98, and 4.82 ± 1.00, respectively. The percentage body weight gain in male and female mice was 25.62% and 25.79%, respectively. The average daily food consumption in grams in male and female mice was 3.47 ± 0.25 and 3.79 ± 0.72, respectively.

Table 1.

Mortality/survival, body weight parameters, and incidence of tumors.

	Male	Female
Number of animals	710	710
Mortality	28	28
Mortality (%)	3.94	3.94
Survival	682	682
Survival (%)	96.06	96.06
Average initial body weight in grams	23.41 ± 0.86	18.74 ± 0.60
Average terminal body weight in grams	29.39 ± 2.20	23.56 ± 0.98
Body weight gain in grams	5.98 ±2.08	4.82 ± 1.00
Body weight gain (%)	25.62	25.79
Average daily food consumption in grams	3.47 ± 0.25	3.79 ± 0.72
Number of animals with tumors	164	167
Incidence of tumors/100 mice (%)	23.05	23.47
Number of animals with lung tumors	87	55
% of lung tumors	53	33
Number of animals with splenic hemangiosarcomas	26	26
% of splenic hemangiosarcomas	16	16
Number of animals with nonsplenic hemangiosarcomas	13	24
% nonsplenic hemangiosarcomas	7	14
Number of animals with all hemangiosarcomas	39	50
% of all hemangiosarcomas	23	30
Number of animals with Harderian gland tumors	11	25
% of Harderian gland tumors	7	15

In 710 male mice, there were a total of 164 male mice with tumors, whereas in 710 female mice there were a total of 167 female mice with tumors. The body weight parameters were compared in animals with or without the common spontaneous tumors. The common spontaneous tumors in male mice included 87 lung tumors (53%), 26 splenic hemangiosarcomas (16%), 13 nonsplenic hemangiosarcomas (7%), 39 all splenic and nonsplenic hemangiosarcomas (23%), and 11 Harderian gland tumors (7%). The common spontaneous tumors in female mice included 55 lung tumors (33%), 26 splenic hemangiosarcomas (16%), 24 nonsplenic hemangiosarcomas (14%), 50 all splenic and nonsplenic hemangiosarcomas (30%), and 25 Harderian gland tumors (15%).

Tables 2 to 6 for males and Tables 7 to 11 for females illustrate the relationship of body weight parameters, such as initial body weights, terminal body weights, food consumption, and body weight gains in grams and percentages with the incidence of common spontaneous tumors at 2 time points, 13 weeks and 26 weeks. There were no statistically significant differences and therefore no relationship with any of the body weight parameters for all tumor types in male mice at both time points, 13 weeks and 26 weeks. In the female mice, there were no statistically significant differences and therefore no relationship with any of the body weight parameters for all tumor types at the 13 weeks time point. At 26 weeks in the female mice, there were no statistically significant differences and therefore no relationship with any of the body weight parameters for lung and Harderian gland tumors. However, in female mice at the 26 weeks time point, increased terminal body weights did have a statistically significant relationship with the incidence of splenic hemangiosarcomas, nonsplenic hemangiosarcomas, and the combined incidence of all hemangiosarcomas. In addition, in female mice, at the 26 weeks time point, the body weight gain in grams and percentages had a statistically significant relationship with the combined incidence of all hemangiosarcomas, but not with the splenic and nonsplenic hemangiosarcomas separately.

Table 2.

Male lung tumors.

Parameter	Tumor present	N	M	SD	Median	p value^a
BW (g) initial	No	558	23.39	1.46	23.30	.2164
BW (g) initial	Yes	87	23.61	1.62	23.80	.2164
Average daily food consumption (g) at 13 weeks	No	544	3.93	0.93	3.67	.3179
Average daily food consumption (g) at 13 weeks	Yes	78	3.91	0.60	3.77	.3179
Average daily food consumption (g) at 26 weeks	No	566	3.78	0.76	3.60	.1005
Average daily food consumption (g) at 26 weeks	Yes	80	3.98	1.49	3.71	.1005
BW gain (g) at 13 weeks	No	550	3.60	2.38	3.10	.7304
BW gain (g) at 13 weeks	Yes	87	3.76	2.94	3.10	.7304
BW gain (g) at 26 weeks	No	558	5.69	3.40	5.10	.1568
BW gain (g) at 26 weeks	Yes	87	5.41	4.35	4.30	.1568
BW gain (%) at 13 weeks	No	550	15.45	10.17	13.38	.6512
BW gain (%) at 13 weeks	Yes	87	15.89	12.23	14.48	.6512
BW gain (%) at 26 weeks	No	558	24.37	14.33	22.20	.1225
BW gain (%) at 26 weeks	Yes	87	22.76	17.91	19.09	.1225
BW (g) terminal	No	558	29.08	3.82	28.30	.4094
BW (g) terminal	Yes	87	29.01	4.94	28.10	.4094

Note: BW = body weight.

^aTesting for differences in median body weight parameters between the group with the tumor present and the group without the tumor.

Table 3.

Male splenic hemangiosarcomas.

Parameter	Tumor present	N	M	SD	Median	p value^a
BW (g) initial	No	558	23.39	1.46	23.30	.6612
BW (g) initial	Yes	26	23.52	1.58	23.50	.6612
Average daily food consumption (g) at 13 weeks	No	544	3.93	0.93	3.67	.3178
Average daily food consumption (g) at 13 weeks	Yes	26	3.73	0.57	3.56	.3178
Average daily food consumption (g) at 26 weeks	No	566	3.78	0.76	3.60	.6378
Average daily food consumption (g) at 26 weeks	Yes	26	3.66	0.49	3.53	.6378
BW gain (g) at 13 weeks	No	550	3.60	2.38	3.10	.2005
BW gain (g) at 13 weeks	Yes	24	4.37	2.64	3.80	.2005
BW gain (g) at 26 weeks	No	558	5.69	3.40	5.10	.5024
BW gain (g) at 26 weeks	Yes	26	6.11	3.40	5.10	.5024
BW gain (%) at 13 weeks	No	550	15.45	10.17	13.38	.2019
BW gain (%) at 13 weeks	Yes	24	18.57	10.76	16.04	.2019
BW gain (%) at 26 weeks	No	558	24.37	14.33	22.20	.5131
BW gain (%) at 26 weeks	Yes	26	25.93	14.09	23.36	.5131
BW (g) terminal	No	558	29.08	3.82	28.30	.5356
BW (g) terminal	Yes	26	29.62	4.02	28.80	.5356

Note: BW = body weight.

^aTesting for differences in median body weight parameters between the group with the tumor present and the group without the tumor.

Table 4.

Male nonsplenic hemangiosarcomas.

Parameter	Tumor present	N	M	SD	Median	p value^a
BW (g) initial	No	558	23.39	1.46	23.30	.0469*
BW (g) initial	Yes	13	24.26	1.44	24.30	.0469*
Average daily food consumption (g) at 13 weeks	No	544	3.93	0.93	3.67	.5609
Average daily food consumption (g) at 13 weeks	Yes	13	3.88	0.45	3.90	.5609
Average daily food consumption (g) at 26 weeks	No	566	3.78	0.76	3.60	.9046
Average daily food consumption (g) at 26 weeks	Yes	13	3.71	0.39	3.71	.9046
BW gain (g) at 13 weeks	No	550	3.60	2.38	3.10	.1566
BW gain (g) at 13 weeks	Yes	13	4.32	2.17	3.80	.1566
BW gain (g) at 26 weeks	No	558	5.69	3.40	5.10	.5231
BW gain (g) at 26 weeks	Yes	13	6.32	3.36	5.80	.5231
BW gain (%) at 13 weeks	No	550	15.45	10.17	13.38	.2517
BW gain (%) at 13 weeks	Yes	13	17.79	8.24	16.24	.2517
BW gain (%) at 26 weeks	No	558	24.37	14.33	22.20	.6449
BW gain (%) at 26 weeks	Yes	13	26.04	13.02	24.79	.6449
BW (g) terminal	No	558	29.08	3.82	28.30	.0767
BW (g) terminal	Yes	13	30.58	3.82	29.20	.0767

Note: BW = body weight.

^aTesting for differences in median body weight parameters between the group with the tumor present and the group without the tumor.

*Indicates a significant difference using a two-sided test at the 5% significance level.

Table 5.

Male splenic and nonsplenic hemangiosarcomas combined.

Parameter	Tumor present	N	M	SD	Median	p value^a
BW (g) initial	No	558	23.39	1.46	23.30	.1399
BW (g) initial	Yes	39	23.76	1.56	23.70	.1399
Average daily food consumption (g) at 13 weeks	No	544	3.93	0.93	3.67	.6328
Average daily food consumption (g) at 13 weeks	Yes	39	3.78	0.53	3.68	.6328
Average daily food consumption (g) at 26 weeks	No	566	3.78	0.76	3.60	.7550
Average daily food consumption (g) at 26 weeks	Yes	39	3.67	0.45	3.63	.7550
BW gain (g) at 13 weeks	No	550	3.60	2.38	3.10	.0654
BW gain (g) at 13 weeks	Yes	37	4.35	2.45	3.80	.0654
BW gain (g) at 26 weeks	No	558	5.69	3.40	5.10	.3667
BW gain (g) at 26 weeks	Yes	39	6.18	3.34	5.60	.3667
BW gain (%) at 13 weeks	No	550	15.45	10.17	13.38	.0925
BW gain (%) at 13 weeks	Yes	37	18.30	9.83	16.24	.0925
BW gain (%) at 26 weeks	No	558	24.37	14.33	22.20	.4302
BW gain (%) at 26 weeks	Yes	39	25.96	13.57	24.65	.4302
BW (g) terminal	No	558	29.08	3.82	28.30	.1335
BW (g) terminal	Yes	39	29.94	3.93	29.00	.1335

Note: BW = body weight.

^aTesting for differences in median body weight parameters between the group with the tumor present and the group without the tumor.

Table 6.

Male Harderian gland tumors.

Parameter	Tumor present	N	M	SD	Median	p value^a
BW (g) initial	No	558	23.39	1.46	23.30	.1003
BW (g) initial	Yes	11	22.88	1.93	22.50	.1003
Average daily food consumption (g) at 13 weeks	No	544	3.93	0.93	3.67	.9881
Average daily food consumption (g) at 13 weeks	Yes	10	3.96	0.91	3.66	.9881
Average daily food consumption (g) at 26 weeks	No	566	3.78	0.76	3.60	.8352
Average daily food consumption (g) at 26 weeks	Yes	10	3.83	0.68	3.60	.8352
BW gain (g) at 13 weeks	No	550	3.60	2.38	3.10	.1616
BW gain (g) at 13 weeks	Yes	11	4.29	1.98	3.70	.1616
BW gain (g) at 26 weeks	No	558	5.69	3.40	5.10	.5584
BW gain (g) at 26 weeks	Yes	11	6.05	2.79	5.60	.5584
BW gain (%) at 13 weeks	No	550	15.45	10.17	13.38	.1475
BW gain (%) at 13 weeks	Yes	11	18.88	8.84	16.67	.1475
BW gain (%) at 26 weeks	No	558	24.37	14.33	22.20	.5442
BW gain (%) at 26 weeks	Yes	11	26.54	12.57	22.95	.5442
BW (g) terminal	No	558	29.08	3.82	28.30	.8968
BW (g) terminal	Yes	11	28.93	3.41	28.40	.8968

Note: BW = body weight.

^aTesting for differences in median body weight parameters between the group with the tumor present and the group without the tumor.

For males and females, the average initial body weights and total tumor counts for each tumor category were analyzed to determine the correlation of coefficient. The results of this analysis are presented in Table 12. These results indicated that in male mice there was no relationship between the total number of tumors for each tumor category with higher initial body weights and thereby possibly higher starting ages. In the female mice, there was also no such relationship between lung tumors, Harderian gland tumors, and splenic hemangiosarcomas. However, in the female mice, there was a statistically significant relation between the nonsplenic hemangiosarcomas and combined incidence of all hemangiosarcomas with the higher initial body weights.

Table 7.

Female lung tumors.

Parameter	Tumor present	N	M	SD	Median	p value^a
BW (g) initial	No	566	18.72	1.24	18.70	.3807
BW (g) initial	Yes	55	18.85	1.32	18.80	.3807
Average daily food consumption (g) at 13 weeks	No	550	4.75	1.22	4.55	.5735
Average daily food consumption (g) at 13 weeks	Yes	49	4.92	1.40	4.75	.5735
Average daily food consumption (g) at 26 weeks	No	570	4.42	1.10	4.16	.6098
Average daily food consumption (g) at 26 weeks	Yes	51	4.66	1.40	4.13	.6098
BW gain (g) at 13 weeks	No	564	3.18	1.48	3.05	.4687
BW gain (g) at 13 weeks	Yes	55	3.08	1.57	2.90	.4687
BW gain (g) at 26 weeks	No	566	4.67	1.89	4.40	.4611
BW gain (g) at 26 weeks	Yes	55	4.36	1.94	4.30	.4611
BW gain (%) at 13 weeks	No	564	17.21	8.40	16.40	.4720
BW gain (%) at 13 weeks	Yes	55	16.67	9.21	15.93	.4720
BW gain (%) at 26 weeks	No	566	25.21	10.88	23.64	.4423
BW gain (%) at 26 weeks	Yes	55	23.49	11.02	22.11	.4423
BW (g) terminal	No	566	23.39	2.04	23.10	.6988
BW (g) terminal	Yes	55	23.21	1.93	23.00	.6988

Note: BW = body weight.

^aTesting for differences in median body weight parameters between the group with the tumor present and the group without the tumor.

Table 8.

Female splenic hemangiosarcomas.

Parameter	Tumor present	N	M	SD	Median	p value^a
BW (g) initial	No	566	18.72	1.24	18.70	.1925
BW (g) initial	Yes	26	19.02	1.03	19.20	.1925
Average daily food consumption (g) at 13 weeks	No	550	4.75	1.22	4.55	.8687
Average daily food consumption (g) at 13 weeks	Yes	24	4.70	1.01	4.76	.8687
Average daily food consumption (g) at 26 weeks	No	570	4.41	1.10	4.16	.9628
Average daily food consumption (g) at 26 weeks	Yes	26	4.44	1.15	4.37	.9628
BW gain (g) at 13 weeks	No	564	3.18	1.48	3.05	.0900
BW gain (g) at 13 weeks	Yes	26	3.75	1.61	3.45	.0900
BW gain (g) at 26 weeks	No	566	4.67	1.89	4.40	.0752
BW gain (g) at 26 weeks	Yes	26	5.14	1.99	5.20	.0752
BW gain (%) at 13 weeks	No	564	17.21	8.40	16.40	.1555
BW gain (%) at 13 weeks	Yes	26	19.94	9.09	18.87	.1555
BW gain (%) at 26 weeks	No	566	25.21	10.88	23.64	.1360
BW gain (%) at 26 weeks	Yes	26	27.27	11.23	27.95	.1360
BW (g) terminal	No	566	23.39	2.04	23.10	.0339*
BW (g) terminal	Yes	26	24.16	1.97	23.90	.0339*

Note: BW = body weight.

^aTesting for differences in median body weight parameters between the group with the tumor present and the group without the tumor.

*Indicates a significant difference using a two-sided test at the 5% significance level.

Table 9.

Female nonsplenic hemangiosarcomas.

Parameter	Tumor present	N	M	SD	Median	p value^a
BW (g) initial	No	566	18.72	1.24	18.70	.1835
BW (g) initial	Yes	24	19.10	1.19	19.30	.1835
Average daily food consumption (g) at 13 weeks	No	550	4.75	1.22	4.55	.4277
Average daily food consumption (g) at 13 weeks	Yes	23	4.55	1.09	4.00	.4277
Average daily food consumption (g) at 26 weeks	No	570	4.41	1.10	4.16	.5374
Average daily food consumption (g) at 26 weeks	Yes	24	4.29	1.02	3.89	.5374
BW gain (g) at 13 weeks	No	564	3.18	1.48	3.05	.5973
BW gain (g) at 13 weeks	Yes	23	3.27	1.54	3.50	.5973
BW gain (g) at 26 weeks	No	566	4.67	1.89	4.40	.0780
BW gain (g) at 26 weeks	Yes	24	5.44	2.91	5.15	.0780
BW gain (%) at 13 weeks	No	564	17.21	8.40	16.40	.7114
BW gain (%) at 13 weeks	Yes	23	17.17	7.91	17.44	.7114
BW gain (%) at 26 weeks	No	566	25.21	10.88	23.64	.1152
BW gain (%) at 26 weeks	Yes	24	28.43	14.22	27.51	.1152
BW (g) terminal	No	566	23.39	2.04	23.10	.0466*
BW (g) terminal	Yes	24	24.54	3.36	24.40	.0466*

Note: BW = body weight.

^aTesting for differences in median body weight parameters between the group with the tumor present and the group without the tumor.

*Indicates a significant difference using a two-sided test at the 5% significance level.

Table 10.

Female splenic and nonsplenic hemangiosarcomas combined.

Parameter	Tumor present	N	M	SD	Median	p vlue^a
BW (g) initial	No	566	18.72	1.24	18.70	.0682
BW (g) initial	Yes	50	19.06	1.10	19.25	.0682
Average daily food consumption (g) at 13 weeks	No	550	4.75	1.22	4.55	.6691
Average daily food consumption (g) at 13 weeks	Yes	47	4.62	1.04	4.34	.6691
Average daily food consumption (g) at 26 weeks	No	570	4.41	1.10	4.16	.7003
Average daily food consumption (g) at 26 weeks	Yes	50	4.37	1.08	4.02	.7003
BW gain (g) at 13 weeks	No	564	3.18	1.48	3.05	.1173
BW gain (g) at 13 weeks	Yes	49	3.52	1.58	3.50	.1173
BW gain (g) at 26 weeks	No	566	4.67	1.89	4.40	.0142*
BW gain (g) at 26 weeks	Yes	50	5.28	2.45	5.20	.0142*
BW gain (%) at 13 weeks	No	564	17.21	8.40	16.40	.2064
BW gain (%) at 13 weeks	Yes	49	18.64	8.58	18.54	.2064
BW gain (%) at 26 weeks	No	566	25.21	10.88	23.64	.0338*
BW gain (%) at 26 weeks	Yes	50	27.82	12.64	27.51	.0338*
BW (g) terminal	No	566	23.39	2.04	23.10	.0044*
BW (g) terminal	Yes	50	24.34	2.71	24.15	.0044*

Note: BW = body weight.

^aTesting for differences in median body weight parameters between the group with the tumor present and the group without the tumor.

*Indicates a significant difference using a two-sided test at the 5% significance level.

Table 11.

Female Harderian gland tumors.

Parameter	Tumor present	N	M	SD	Median	p value^a
BW (g) initial	No	566	18.72	1.24	18.70	.4663
BW (g) initial	Yes	25	18.40	1.59	18.80	.4663
Average daily food consumption (g) at 13 weeks	No	550	4.75	1.22	4.55	.0666
Average daily food consumption (g) at 13 weeks	Yes	24	4.45	1.49	3.81	.0666
Average daily food consumption (g) at 26 weeks	No	570	4.41	1.10	4.16	.2505
Average daily food consumption (g) at 26 weeks	Yes	24	4.30	1.37	3.74	.2505
BW gain (g) at 13 weeks	No	564	3.18	1.48	3.05	.9607
BW gain (g) at 13 weeks	Yes	25	3.18	1.38	3.00	.9607
BW gain (g) at 26 weeks	No	566	4.67	1.89	4.40	.7670
BW gain (g) at 26 weeks	Yes	25	4.41	1.92	4.40	.7670
BW gain (%) at 13 weeks	No	564	17.21	8.40	16.40	.8655
BW gain (%) at 13 weeks	Yes	25	17.81	9.25	17.03	.8655
BW gain (%) at 26 weeks	No	566	25.21	10.88	23.64	.9804
BW gain (%) at 26 weeks	Yes	25	24.38	11.15	23.40	.9804
BW (g) terminal	No	566	23.39	2.04	23.10	.1475
BW (g) terminal	Yes	25	22.81	2.19	22.40	.1475

Note: BW = body weight.

^aTesting for differences in median body weight parameters between the group with the tumor present and the group without the tumor.

Table 12.

Relationship between initial body weights and tumors.

Tumor category	Males		Females
Tumor category	Correlation	p value	Correlation	p value
All tumors	−.05	.82	.26	.20
All lung tumors	.03	.89	.20	.34
All Harderian gland tumors	−.25	.21	−.29	.15
Splenic hemangiosarcomas	.01	.96	.28	.17
Nonsplenic hemangiosarcomas	.08	.69	.41	.04*
All hemangiosarcomas	.06	.78	.55	.01*

*Indicates statistical significance.

Discussion

The average initial body weight of the Tg.rasH2 male mice in our studies expressed as M ± SD was 23.41 ± 0.86 g and that of female mice was 18.74 ± 0.60 g, when the mice were placed on the study between 6 and 10 weeks of age. The body weights of the Tg.rasH2 mice are 80 to 90% of their wild-type counterparts, namely C57BL/6 and the BALB/c mice (Taconic information 2013; Yamamoto et al. 1997). The initial body weights of CD1 and B6C3F1 mice when placed on study at 6 to 8 weeks of age are about 20 to 25% more than the Tg.rasH2 mice (Charles River information 2013; Harlan information 2013). Thus, in general, the Tg.rasH2 mice are smaller than mouse strains commonly used in conventional 2-year studies. The initial body weights are tied to the age of the mice at the start of the study. At the start of the study, these mice are 6 to 10 weeks old and by the completion of the study these mice would be 32 to 36 weeks old. It is important to start the study in the range of 6 to 10 weeks of age, as at around 40 weeks of age the mortality in these mice substantially increases, more so in females than in males, due to increased development of spontaneous tumors (Yamamoto et al. 1998).

The body weight parameters did not have any statistically significant relationship with any of the tumor types in both sexes of mice at 13 weeks. This suggests that at least at 13 weeks these body weight parameters are less likely to have any influence on future development of these tumors noted at 26 weeks. In male mice, these body weight parameters did not have any statistically significant relationship with any of the tumor types at 26 weeks. At the 26 weeks time point, the female mice did not have any statistically significant relationship with lung and Harderian gland tumors. However, in female mice at the 26 weeks time point, increased terminal body weights did have a statistically significant relationship with the incidence of splenic hemangiosarcomas, nonsplenic hemangiosarcomas, and the combined incidence of all hemangiosarcomas. In addition, at the 26 weeks time point in female mice, increased body weight gains in grams and percentages had statistically significant relationship with the combined incidence of all hemangiosarcomas, but not with the splenic and nonsplenic hemangiosarcomas separately. At our facility, although the starting age of the mice between studies has varied between 6 and 10 weeks, every attempt was made to initiate the study at the starting age of 8 weeks. However, the starting age depended on the breeding schedules of the supplier, Taconic. Nevertheless, in any given study, the starting age of the males and females was similar. The data analyzed to determine the coefficient of correlation showed that there was no positive correlation between the number of tumors for each tumor category with higher initial body weights and thereby higher starting ages in male mice. This analysis also showed that there was no positive relationship between the lung tumors, Harderian gland tumors, and splenic hemangiosarcomas in female mice. However, there was a statistically significant relationship between the higher initial body weights and nonsplenic hemangiosarcomas as well as combined incidence of all hemangiosarcomas in female mice. Clearly, the positive relationship between higher initial body weights and combined incidence of all hemangiosarcomas in female mice is due to nonsplenic hemangiosarcomas, as the splenic hemangiosarcomas did not demonstrate this relationship.

The cause for having a relationship with the splenic and nonsplenic hemangiosarcomas in female mice only but not in male mice is not clear. However, it needs to be pointed out that in terms of body weight gain in percentages, the female mice (25.79%) showed only slight gain compared to the male mice (25.62%). Also the average daily food consumption expressed as M ± SD in grams in female mice (3.79 ± 0.72) was more than the male mice (3.47 ± 0.25). These differences may be important because despite the initial body weights of female mice being 4 to 5 g lower than the males, both the food consumption and the body weight gain in percentages were higher in female mice. Given the fact that the incidence of splenic hemangiosarcomas was identical in both sexes at 16%, it is not likely that these splenic hemangiosarcomas would have any influence on terminal body weights and weight gain in percentage in female mice alone and not in male mice. The incidence of nonsplenic hemangiosarcomas was double in female mice (14%) compared to the male mice (7%). The majority of the nonsplenic hemangiosarcomas involved the reproductive system in both male and female mice; however, the hemangiosarcomas involving the reproductive system of female (uterus, vagina, and ovary) were double in number (Paranjpe, Elbekai, et al. 2013) compared to the male reproductive organs (testes, epididymides, and seminal vesicles). Also the nonsplenic hemangiosarcomas involving the skin/subcutis were much higher in number in female mice as compared to the male mice (Paranjpe, Elbekai, et al. 2013). We have consistently observed enlargement of spleens and therefore increase in their weights due to extramedullary hematopoiesis in mice of both sexes whenever nonsplenic hemangiosarcomas were present in the same animals (Paranjpe, Shah, et al. 2013). Because the incidence of nonsplenic hemangiosarcomas is double in female mice than the male mice, the number of female mice with splenic enlargement and therefore increased splenic weights due to extramedullary hematopoiesis are also expected to be double in number compared to the male mice. Based on all these factors, it is likely that the association noted between the increased terminal body weights and body weight gain with the hemangiosarcomas in female mice only but not in male mice may have been due to a combination of factors such as more average daily food consumption, more body weight gain in percentages, increased incidence of nonsplenic hemangiosarcomas involving the reproductive system and skin/subcutis, and secondary splenic enlargement of the spleen due to extramedullary hematopoiesis. In addition, the association between the increased initial body weights and nonsplenic hemangiosarcomas in female mice is noteworthy.

The incidence of lung tumors in male mice (53%) was considerably higher than in female mice (33%); whereas the incidence of Harderian gland tumors in male mice (7%) was much lower than in the female mice (15%). However, neither lung nor Harderian gland tumors demonstrated any statistically significant relationship with any of the body weight parameters in both sexes.

The mechanistic relationship between increased food consumption, increased body weights, hormonal perturbations, increased incidence of tumors, and increased mortality that eventually complicate the interpretation of 2-year rodent studies has been widely reported for the 2-year F344 rats, Sprague-Dawley rats, CD-1 mice, and B6C3F1 mice (Allaben et al. 1996; Biegel et al. 2001; Hart et al. 1995; Haseman et al. 1997; Haseman, Hailey, and Morris 1998; Keenan and Soper 1995; Keenan et al. 1995; Leakey, Seng, and Allaben 2003; Nohynek et al. 1993; Nunez et al. 2008; Rao 1996; Roe 1981, 1993; Seilkop 1995; Sistare et al. 2011; Turturro et al. 1996). Rather than mechanisms that involve alterations in body weight parameters and hormonal perturbations in 2-year rodent models, the mechanism of tumor production in Tg.rasH2 mouse involves overexpression of C-Ha-ras gene product, p21 (Maruyama et al. 2001; Saitoh et al. 1990; Sekiya et al. 1985; Tamaoli 2001; Usui et al. 2001; Yamamoto et al. 1998). These mechanistic differences also explain the differences in the types of spontaneous tumors in 2-year rodents and Tg.rasH2 mice. To name a few, the common tumors in 2-year rodents include tumors of pituitary, thyroid, testes, liver, and mammary glands; all of which are influenced by the combination of mechanisms such as increased food consumption, increased body weights, and hormonal perturbations (Allaben et al. 1996; Biegel et al. 2001; Hart et al. 1995; Haseman, Bourbina, and Eustis 1994; Haseman 1995a, ^1995b; Haseman et al. 1997; Haseman, Hailey, and Morris 1998; Kari and Abdo 1995; Keenan and Soper 1995; Keenan et al. 1995; Leakey, Seng, and Allaben 2003; Nohynek et al. 1993; Nunez et al. 2008; Rao 1996; Rao, Piegorsch, and Haseman 1987; Roe 1981, 1993; Seilkop 1995; Sistare et al. 2011; Thurman et al. 1994; Turturro et al. 1996; Witt, Sheldon, and Thurman 1991). In contrast, the common tumors in Tg.rasH2 include lung tumors, hemangiosarcomas, and Harderian gland tumors (Nambiar, Turnquist, and Morton 2012; Paranjpe, Elbekai, et al. 2013), none of which are likely to be influenced by hormonal perturbations. Among all of the nonsplenic hemangiosarcomas, the incidence of hemangiosarcomas involving the male and female reproductive system was higher (Paranjpe, Elbekai, et al. 2013); however, these hemangiosarcomas of the reproductive system in Tg.rasH2 mice are not considered to be hormonally induced.

In summary, at both 13 weeks and 26 weeks, the body weight parameters did not have any statistically significant relationship with the spontaneous tumors in the Tg.rasH2 male mice, namely lung and Harderian gland tumors and splenic and nonsplenic hemangiosarcomas. These parameters also did not have any significant relationship with any of the tumor types in female mice at the 13 weeks time point. At the 26 weeks time point, these parameters also did not have any significant relationship with lung and Harderian gland tumors in female mice. However, at the 26 weeks time point, these parameters did have a statistically significant relationship with splenic hemangiosarcomas, nonsplenic hemangiosarcomas, and combination of all hemangiosarcomas in female mice. The causes of this relationship in the female mice alone may be multifold and may include a combination of factors such as:

Increased daily food consumption in female mice compared to male mice

Increased body weight gains in percentage in female mice compared to the male mice

Increased incidence of nonsplenic hemangiosarcomas in female mice compared to the male mice, particularly those involving the female reproductive system and skin/subcutis

The tumor, hemangiosarcoma, itself contributing to the higher terminal body weights in tumor-bearing animals

Increased initial body weights that may have contributed to the increased incidence of nonsplenic hemangiosarcomas in female mice

Secondary extramedullary hematopoiesis that causes enlargement of spleens in mice with nonsplenic hemangiosarcomas.

Footnotes

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Abbreviations

References

Allaben

W. T.

Turturro

Leakey

J. E. A.

Seng

J. E.

Hart

R. W

. (1996). Points-to-consider documents: The need for dietary control for the reduction of experimental variability within animal assays and the use of dietary restriction to achieve dietary control. Toxicol Pathol 24, 776–81.

American Cancer Society. (2012). Body weight and cancer risk—Excess body weight: A major health issue in America. Accessed November 12, 2012. http://www.cancer.org/acs/groups/cid/documents/webcontent/002578-pdf.pdf.

Biegel

L. B.

Hurtt

M. E.

Frame

S. R.

O’Connor

J. C.

Cook

J. C

. (2001). Mechanisms of extrahepatic tumor induction by peroxisome proliferators in male CD rats. Toxicol Sci 60, 44–55.

Charles River Information. (2013). CD-1 IGS Mouse Model Information Sheet. Accessed June 19, 2013. http://www.criver.com/SiteCollectionDocuments/rm_rm_d_CD1_mouse.pdf.

Harlan Information. (2013). Research models. Accessed June 19, 2013. http://www.harlan.com/online_literature/research_models.hl.

Hart

R. W.

Keenan

Turturro

Abdo

K. M.

Leakey

J. E. A.

Lyn-Cook

. (1995). Caloric restriction and toxicity. Fundam Appl Toxicol 25, 184–95.

Haseman

J. K

. (1995a). Data analysis: Statistical analysis and use of historical control data. Regul Toxicol Pharmacol 21, 52–59.

Haseman

J. K

. (1995b). Statistical considerations in long term dietary restriction studies. In Dietary Restriction: Implications for the Design and Interpretation of Toxicity and Carcinogenicity Studies ( Hart

Neumann

Robertson

, eds.), pp. 141−54. ILSI Press, Washington, DC.

Haseman

J. K.

Bourbina

Eustis

. (1994). The effect of individual housing and other experimental design factors on tumor incidence in B6C3F1 mice. Fundam Appl Toxicol 23, 44–52.

10.

Haseman

J. K.

Hailey

J. R.

Morris

R. W

. (1998). Spontaneous neoplasm incidences in Fischer 344 rats and B6C3F1 mice in two-year carcinogenicity studies: A National Toxicology Program Update. Toxicol Pathol 26, 428–41.

11.

Haseman

J. K.

Young

Eustis

S. L.

Hailey

J. R

. (1997). Body weight-tumor incidence correlations in long-term rodent carcinogenicity studies. Toxicol Pathol 25, 256–63.

12.

Hollander

Wolfe

D. A.

(1973). Nonparametric Statistical Methods pp. 67−75. John Wiley, New York, NY.

13.

Jacobs

A. C.

Hatfield

K. P

. (2013). History of chronic toxicity and animal toxicity studies for pharmaceuticals. Vet Path 50, 324–33.

14.

Kari

Abdo

. (1995). The sensitivity of the NTP bioassay for carcinogen hazard evaluation can be modulated by dietary restriction. In Dietary Restriction: Implications for the Design and Interpretation of Toxicity and Carcinogenicity Studies ( Hart

Neumann

Robertson

, eds.), pp. 63−78. ILSI Press, Washington, DC.

15.

Keenan

K. P.

Soper

K. A

. (1995). The effects of ad libitum overfeeding and moderate dietary restriction on Sprague-Dawley rat survival, spontaneous carcinogenesis, chronic disease, and the toxicological response to pharmaceuticals. In Dietary Restriction: Implications for the Design and Interpretation of Toxicity and Carcinogenicity Studies ( Hart

R. W.

Neumann

D. A.

Robertson

R. T.

, eds.), pp. 99−126. International Life Sciences Institute, Washington, DC.

16.

Keenan

K. P.

Soper

K. A.

Hertzog

P. R.

Gumprecht

L. A.

Smith

P. F.

Mattson

B. A.

Ballam

G. C.

Clark

R. L

. (1995). Diet, overfeeding, and moderate dietary restriction in control Sprague-Dawley rats: II. Effects on age-related proliferative and degenerative lesions. Toxicol Pathol 23, 287–302.

17.

Leakey

J. E. A.

Seng

J. E.

Allaben

W. T

. (2003). Body weight considerations in the B6C3F₁ mouse and the use of dietary control to standardize background tumor incidence in chronic bioassays. Toxicol Appl Pharm 193, 237–65.

18.

Maruyama

Tomisawa

Wakana

Yamazaki

Kijima

Suemizu

. (2001). Overexpression of human H-ras transgene is responsible for tumors induced by chemical carcinogens in mice. Oncol Rep 8, 233–37.

19.

Nambiar

P. R.

Turnquist

S. E.

Morton

. (2012). Spontaneous tumor incidence in rasH2 mice: Review of internal data and published literature. Toxicol Pathol 40, 614–23.

20.

Nohynek

G. J.

Longeart

Geffray

Provost

J. P.

Lodole

. (1993). Fat, frail and dying young: Survival, body weight and pathology of the Charles River Sprague-Dawley-derived rat prior to and since the introduction of the VAF^R variant in 1988. Hum Exp Toxicol 12, 87–98.

21.

Nunez

N. P.

Perkins

S. N.

Smith

N. C.

Berrigan

Berendes

D. M.

Varticovski

Barrett

J. C.

Hursting

S. D

. (2008).Obesity accelerates mouse mammary tumor growth in the absence of ovarian hormones. Nutr Cancer 60, 534–41.

22.

Paranjpe

M. G.

Elbekai

R. H.

Shah

S. A.

Hickman

Wenk

M. L.

Zahalka

E. A

. (2013). Historical control data of spontaneous tumors in transgenic CByB6F1-Tg(HRAS)2Jic (Tg.rasH2) mice. Int J Toxicol 32, 48–57.

23.

Paranjpe

M. G.

Shah

S. A.

Denton

M. D.

Elbekai

R. H

. (2013). Incidence of spontaneous non-neoplastic lesions in transgenic CByB6F1-Tg(HRAS)2Jic (Tg.rasH2) mice. Toxicol Pathol. 41, 1137–1145.

24.

Rao

G. N

. (1996). Influence of diet on tumors of hormonal tissue. Prog Clin Biol Res 394, 41–56.

25.

Rao

G. N.

Piegorsch

W. W.

Haseman

J. K

. (1987). Influence of body weight on the incidence of spontaneous tumors in rats and mice of tong-term studies. Am J Clin Nutr 45, 252–60.

26.

Rodgers

J. L.

Nicewander

W. A

. (1988). Thirteen ways to look at the correlation coefficient. Am Stat 42, 59–66.

27.

Roe

F. J. C

. (1981). Are nutritionists worried about the epidemic of tumors in laboratory animals? Proc Nutr Soc 40, 57–65.

28.

Roe

F. J. C

. (1993). What does carcinogenicity mean and how should we test for it? Food Chem Toxicol 31, 225–29.

29.

Saitoh

Kimura

Takahashi

Yokoyama

Nomura

Izawa

Sekiya

Nishimura

Katsuki

. (1990). Most tumors in transgenic mice with human c-Ha-ras gene contained somatically activated transgenes. Oncogene 5, 1195–200.

30.

SAS® Statistical Software. (2002–2003). Version 9.2. SAS Institute, Cary, NC.

31.

Seilkop

S. K

. (1995). The effect of body weight on tumor incidence and carcinogenicity testing in B6C3F1 mice and F344 rats. Fundam Appl Toxicol 24, 247–59.

32.

Sekiya

Prassolov

V. S.

Fushimi

Nishimura

. (1985). Transforming activity of the c-Ha-ras oncogene having two point mutations in codons 12 and 61. Jpn J Cancer Res 76, 851–55.

33.

Sistare

F. D.

Morton

Alden

Christensen

Keller

Jonghe

S. D.

Storer

R. D.

Reddy

M. V.

Kraynak

Trela

Bienvenu

J. G.

Bjurström

Bosmans

Brewster

Colman

Dominick

Evans

Hailey

J. R.

Kinter

Liu

Mahrt

Marien

Myer

Perry

Potenta

Roth

Sherratt

Singer

Slim

Soper

Fransson-Steen

Stoltz

Turner

Turnquist

van Heerden

Woicke

DeGeorge

J. J

. (2011). An analysis of pharmaceutical experience with decades of rat carcinogenicity testing: Support for a proposal to modify current regulatory guidelines. Toxicol Pathol 39, 716–44.

34.

Taconic Information. (2013). Accessed June 19, 2013. http://www.taconic.com/user-assets/Documents/rash2.pdf.

35.

Tamaoli

. (2001). The rasH2 transgenic mouse: Nature of the model and mechanistic studies on tumorigenesis. Toxicol Pathol 29, 81–89.

36.

Thurman

J. D.

Bucci

T. J.

Hart

R. W.

Turturro

. (1994). Survival, body weight, and spontaneous neoplasms in ad libitum-fed and food-restricted Fischer-344 rats. Toxicol Pathol 22, 1–9.

37.

Turturro

Duffy

Hart

R. W.

Allaben

W. T

. (1996). Rational use of dietary control in toxicity studies—B6C3F1 mouse. Toxicol Pathol 24, 769–75.

38.

Usui

Mutai

Hisada

Takoaka

Soper

K. A.

Mccullough

Alden

. (2001). CB6F1-rasH2 mouse: Overview of available data. Toxicol Pathol 29, 90–108.

39.

Witt

W. M.

Sheldon

W. G.

Thurman

J. D

. (1991). Pathological endpoints in dietary restricted rodents: Fischer 344 rats and B6C3F1 mice. In Biological Effects of Dietary Restriction ( Fishbein

, ed.), pp.73−86. Springer-Verlag, New York, NY.

40.

Yamamoto

Hayashi

Mitsumori

Nomura

. (1997). Rapid carcinogenicity testing with transgenic mice harboring human prototype c-Ha-ras gene. Lab Anim Sci 47, 121–26.

41.

Yamamoto

Urano

Koizumi

Wakana

Hioki

Mitsumori

Kurokawa

Hayashi

Nomura

. (1998). Validation of transgenic mice carrying the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing. Environ Health Perspect 106, 57–69.